Mouse study links higher hippocampal 2-AG with early fluoxetine response

2-AG as a potential biomarker for predicting response to short-term fluoxetine treatment in a mouse model of depression.

Translational psychiatry • • Highly Relevant
🤖

AI Summary

The study asked whether endocannabinoid levels could help identify early response to fluoxetine. Researchers used male mice exposed to chronic unpredictable mild stress, a model of depression, and gave fluoxetine during the final week of the five-week protocol. They measured brain chemicals in the hippocampus and prefrontal cortex and observed behavioral improvement after treatment.

The improvement was accompanied by increased hippocampal 2-arachidonoylglycerol (2-AG) and reduced GABA and glutamate in the prefrontal cortex. The authors suggest that 2-AG may be a marker of early fluoxetine response. This is an abstract-based summary: the findings come from a mouse study and do not establish that 2-AG predicts antidepressant response in people or that the changes caused the behavioral improvement. The abstract does not report sample size or quantitative effect estimates.

💡 Key Findings

1
In stressed male mice, behavioral improvement after short-term fluoxetine treatment was accompanied by increased hippocampal 2-AG.
High
80%
2
Treatment-related behavioral improvement was also accompanied by reduced GABA and glutamate in the prefrontal cortex.
High
80%
3
The authors propose that increased 2-AG may predict early fluoxetine response, but this mouse study cannot establish predictive value in humans or show that 2-AG changes cause improvement.
High
90%

📄 Original Abstract

Major depressive disorder (MDD) is a complex psychiatric condition with significant individual and social impact and marked variability in treatment response. Identifying biomarkers that predict antidepressant efficacy remains a major challenge, and metabolomic approaches offer a powerful tool to uncover biochemical changes associated with depression and treatment outcome. The prefrontal cortex and the hippocampus are key brain regions involved in the pathophysiology of MDD and antidepressant response. Fluoxetine, one of the most commonly prescribed antidepressants, influences not only serotonergic signaling but also the endocannabinoid system. Accordingly, evaluating endocannabinoid levels might provide critical insight into their contribution and the effect of fluoxetine. To identify biomarkers associated with early antidepressant response, male mice were exposed for 5 weeks to the chronic unpredictable mild stress (CUMS) protocol, with fluoxetine treatment administered during the final week. Liquid chromatography-tandem mass spectrometry analyses of hippocampal and prefrontal cortex samples revealed that behavioral improvement following short-term fluoxetine treatment was accompanied by increased hippocampal 2-arachidonoylglycerol (2-AG), along with reduced GABA and glutamate levels in the prefrontal cortex. These findings suggest that increased 2-AG levels may predict early response to fluoxetine.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.